Switch theme
Sign up to access all valuation multiples
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
1818
11.0K+
Last FY Revenue $2.7B
Last FY EBITDA $279M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Paul Hartmann achieved revenue of $2.7B and an EBITDA of $279M.
Paul Hartmann expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Paul Hartmann valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $2.7B | XXX | XXX | XXX |
| Gross Profit | XXX | $1.6B | XXX | XXX | XXX |
| Gross Margin | XXX | 60% | XXX | XXX | XXX |
| EBITDA | XXX | $279M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 10% | XXX | XXX | XXX |
| EBIT | XXX | $128M | XXX | XXX | XXX |
| EBIT Margin | XXX | 5% | XXX | XXX | XXX |
| Net Profit | XXX | $122M | XXX | XXX | XXX |
| Net Margin | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | $49.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Paul Hartmann's stock price is EUR 240 (or $270).
Paul Hartmann has current market cap of EUR 852M (or $957M), and EV of EUR 982M (or $1.1B).
See Paul Hartmann trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $957M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Paul Hartmann has market cap of $957M and EV of $1.1B.
Paul Hartmann's trades at 0.4x EV/Revenue multiple, and 3.9x EV/EBITDA.
Equity research analysts estimate Paul Hartmann's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Paul Hartmann's P/E ratio is not available.
See valuation multiples for Paul Hartmann and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $957M | XXX | $957M | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 8.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 7.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 16.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPaul Hartmann's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Paul Hartmann's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Paul Hartmann's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Paul Hartmann and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Paul Hartmann acquired XXX companies to date.
Last acquisition by Paul Hartmann was XXXXXXXX, XXXXX XXXXX XXXXXX . Paul Hartmann acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Paul Hartmann founded? | Paul Hartmann was founded in 1818. |
| Where is Paul Hartmann headquartered? | Paul Hartmann is headquartered in Germany. |
| How many employees does Paul Hartmann have? | As of today, Paul Hartmann has 11.0K+ employees. |
| Is Paul Hartmann publicy listed? | Yes, Paul Hartmann is a public company listed on FRA. |
| What is the stock symbol of Paul Hartmann? | Paul Hartmann trades under PHH2 ticker. |
| Who are competitors of Paul Hartmann? | Similar companies to Paul Hartmann include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Paul Hartmann? | Paul Hartmann's current market cap is $957M |
| Is Paul Hartmann profitable? | Yes, Paul Hartmann is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
